What a GLP-1 Actually Costs a Mother, With and Without Insurance

There is no single price for a GLP-1. There are three, they differ by hundreds of dollars a month, and which one applies to you has almost nothing to do with your health and almost everything to do with who insures you.

The advertised price is usually the starting dose

Start here, because it is the number most likely to catch you out. Eli Lilly promotes self-pay Zepbound at $299 per month — and on the same page states that the regular price for a one-month supply of the single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg and 15 mg.¹ The same page notes that 2.5 mg "is a starting dose and is not approved as a maintenance dose."¹

So the advertised figure is the price of the one dose you are not meant to stay on. If you titrate to a maintenance dose the way the label intends, the honest budget is not $299 but something between $499 and $699 — before the introductory offers expire.

Novo Nordisk's structure is flatter and easier to plan around. Its own price guide lists self-pay Wegovy at $349 a month across 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, with a limited-time $199 a month for the first two months, new patients only, and the oral form at $149 a month at 1.5 mg rising to $299 at 9 mg and 25 mg.² One price at every injectable dose is a meaningfully different proposition from one that triples as you titrate — and it is the sort of difference a comparison of headline numbers hides completely.

If you are on Medicare, the answer changed in July

For decades, federal law barred Medicare Part D from covering a drug prescribed for weight loss. That is still the statute — but since July 1, 2026 there has been a route around it. CMS is running a time-limited demonstration called the Medicare GLP-1 Bridge, and eligible Part D beneficiaries pay a $50 copay for covered GLP-1s through December 31, 2027.³

The covered list is specific: Foundayo, Wegovy (injection and tablets), and Zepbound — KwikPen formulation only.⁴ Eligibility turns on BMI at the time therapy started, not today: BMI 35 or above, or 30 or above with one of a listed set of conditions, or 27 or above with a diagnosis such as pre-diabetes.⁴ Because it is assessed at initiation, someone who started at 37 and is now 34 still qualifies — CMS uses exactly that example.⁴

Three details are easy to miss and all of them cost money. The Bridge sits outside the Part D benefit, so your deductible does not apply — but the $50 also does not count toward your true out-of-pocket total, and no low-income subsidy applies to it.³ For a beneficiary who would otherwise reach the catastrophic phase, that is not a small footnote. Prior authorization is required, handled through a single central processor.³ The Bridge is explicitly a bridge: it exists while CMS tests a longer-term route to covering these drugs, and the Part D portion of that wider model has already been delayed once.⁶

If you have employer insurance, it depends on where you work

This is the part that feels arbitrary because it is. In KFF's 2025 employer survey, coverage of GLP-1s for weight loss ran 16% at firms with 200-999 workers, 30% at 1,000-4,999, and 43% at firms of 5,000 or more.⁵ The same drug, the same diagnosis, the same body — and roughly a one-in-six or a four-in-ten chance depending on the size of your employer.

And coverage is not the end of it. Among employers who do cover these drugs for weight loss, 34% require enrollees to meet with a dietitian, case manager or therapist, or to join a lifestyle program first.⁵ If you are a mother working out how to fit treatment around a job and small children, that requirement is a real cost even when the drug is free — and it is worth asking about before you count on the benefit.

Before you assume you are not covered, check the specific plan document rather than the drug's name: many plans that exclude "weight loss" cover the same molecule for sleep apnea or cardiovascular risk reduction, which are separate approved uses.

Where compounded programs fit

If none of the above reaches you, the compounded market is where most mothers end up looking, and it is genuinely cheaper. Across the providers we track, the lowest disclosed month-to-month compounded semaglutide price sat at $69 a month in August 2026, with a median of $179 among those that publish one at all — against $349 for a brand pen at any dose.

The trade is not subtle. Compounded drugs are not FDA-approved finished products, the approval covering the brand pen does not extend to them, and a low sticker attached to no clinical oversight is not the cheaper option. Read how to choose a provider before you read a price list, and treat any figure quoted only after an intake as a figure that can move.

What to do this week

If you are on Medicare, ask your prescriber about the GLP-1 Bridge by name and confirm your BMI at initiation is documented. If you have employer insurance, pull the plan's formulary and search for the molecule rather than the words "weight loss". If you are paying cash, get the price at your maintenance dose, not the starter — and write down the date the introductory offer ends, because both manufacturers' current offers carry expiry dates.

A note on how solid this is. Unusually for this site, none of it rests on clinical trial data — these are administrative facts, and they are as strong as evidence gets in one sense: every figure here is a published price or a stated rule, read from the issuer's own page in August 2026 rather than from a summary. They are also the least durable facts we publish. A trial result from 2021 will still be true next year; a price or a coverage rule can change the week after this sentence, and both manufacturers' current offers carry printed expiry dates. Treat the structure as reliable and every number as a reading with a date on it.

None of this is medical advice. Check your own figures at the source before you plan around them.